Medicines/Item |
Section |
Status |
Link Name / Link URL |
Abatacept |
10.01.03 |
Formulary
|
NICE TA195 August 2010: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
Abatacept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
Abatacept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Abemaciclib |
08.01.05 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
Abemaciclib |
08.01.05 |
Formulary
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
Acetylcysteine |
03.11 |
Formulary
|
NICE CG163 May 17 update: Idiopathic pulmonary fibrosis in adults: diagnosis and management |
Adalimumab |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
Adalimumab |
13.05.03 |
Formulary
|
NICE TA146 Adalimumab for the treatment of adults with psoriasis |
Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
Adrenaline / epinephrine |
03.04.03 |
Formulary
|
NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment |
Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
Aflibercept |
08.01.05 |
Non Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA346: Aflibercept for treating diabetic macular oedema |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
Alectinib |
08.01.05 |
Non Formulary
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
Alemtuzumab |
08.02.03 |
Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Alitretinoin |
13.05.01 |
Formulary
|
NICE TA177 Alitretinoin for the treatment of severe chronic hand eczema Aug 2009 |
Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
Amantadine |
04.09.01 |
Formulary
|
NICE CG186 Multiple sclerosis in adults: management (Nov 19 update) |
Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156: Anti-D in pregnant women |
Anti-D (Rh0) Immunoglobulin |
14.05 |
Formulary
|
NICE TA156 (Aug 2008) - Routine antenatal anti-D prophylaxis for women who are rhesus D negative |
Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for AF |
Apixaban |
02.08.02 |
Formulary
|
NICE TA341 June 2015: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
Apixaban |
02.08.02 |
Formulary
|
NICE TA341 Treatment and secondary prevention of DVT and/or PE |
Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Prevention of stroke and systemic embolism in people with nonvalvular AF |
Apixaban |
02.08.02 |
Formulary
|
NICE TA245: Prevention of VTE after elective hip or knee replacement |
Apixaban |
02.08.02 |
Formulary
|
NICE TA245 Jan 2012: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
Apremilast |
10.01.03 |
Formulary
|
NICE TA433 Apremilast for treating active psoriatic arthritis Feb 2017 |
Apremilast |
13.05.03 |
Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
Apremilast |
13.05.03 |
Formulary
|
NICE TA433 : Apremilast for treating active psoriatic arthritis |
Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA448 : Etelcalcetide for treating secondary hyperparathyroidism |
Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA456: Baricitinib for moderate to severe rheumatoid arthritis |
Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder |
Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia |
Atezolizumab |
08.01.05 |
Formulary
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
Atezolizumab |
08.01.05 |
Formulary
|
NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma |
Atezolizumab |
08.01.05 |
Formulary
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
Atezolizumab |
08.01.05 |
Formulary
|
NICE TA520 : Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
Atezolizumab |
08.01.05 |
Formulary
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
Atomoxetine |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
Atorvastatin |
02.12 |
Formulary
|
NICE CG181 Sept 2016: Cardiovascular disease: risk assessment and reduction, including lipid modification |
Avatrombopag |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
Avelumab |
08.01.05 |
Formulary
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma |
Avelumab |
08.01.05 |
Formulary
|
NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma |
Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for advanced renal cell carcinoma |
Axitinib |
08.01.05 |
Formulary
|
NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma |
Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: azacitidine for myelodysplastic syndromes |
Baricitinib |
10.01.03 |
Formulary
|
NICE TA466 August 2017: Baricitinib for moderate to severe rheumatoid arthritis |
Basiliximab |
08.02.02 |
Non Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
Basiliximab |
08.02.02 |
Non Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
Belimumab |
10.01.03 |
Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
Bendamustine |
08.01.01 |
Formulary
|
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA263: Breast cancer with capecitabine |
Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA214: Breast Cancer with taxane |
Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
Bezafibrate |
02.12 |
Formulary
|
NICE: Do Not Do Recommendation |
Bismuth subsalicylate |
01.03.03 |
Formulary
|
NICE Pathway: Helicobacter pylori testing and eradication in adults |
Bisphosphonates |
09.05.01.02 |
Non Formulary
|
NICE TA464 : Bisphosphonates for treating osteoporos |
Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230 : Bivalirudin for the treatment of STEMI, 2011 |
Blinatumomab |
08.02 |
Formulary
|
NICE TA450 : Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: 1st line treatment of multiple myeloma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Multiple myeloma - bortezomib |
Bosutinib |
08.01.05 |
Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
Botulinum A toxin |
04.07.04.02 |
Formulary
|
NICE TA 260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine June 2012 |
Botulinum A toxin |
04.09.03 |
Formulary
|
NICE TA260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine June 2012 |
Botulinum A toxin |
04.09.03 |
Formulary
|
NICE TA605 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea October 2019 |
Botulinum toxin |
07.04.03 |
Formulary
|
NICE NG123 June 2019: Urinary incontinence and pelvic organ prolapse in women: management |
Brentuximab |
08.01.05 |
Formulary
|
NICE TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
Brentuximab |
08.01.05 |
Formulary
|
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
Brentuximab |
08.01.05 |
Formulary
|
NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
Brentuximab |
08.01.05 |
Formulary
|
NICE TA641 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
Brigatinib |
08.01.05 |
Formulary
|
NICE TA571 :Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
Brodalumab |
13.05.03 |
Formulary
|
NICE TA511 Brodalumab for treating moderate to severe plaque psoriasis March 2018 |
Brodalumab |
13.05 |
Formulary
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
Brolucizumab |
11.08.02 |
Formulary
|
NICE TA672: Brolucizumab for treating wet age-related macular degeneration |
Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin for type 2 diabetes |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315 June 2014: Canagliflozin in combination therapy for treating type 2 diabetes |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 May 2016: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Cangrelor |
02.09 |
Non Formulary
|
NICE TA351: Reducing Artherothrombotic Events |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
Caplacizumab |
09.01.04 |
Formulary
|
NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura |
Carfilzomib |
08.01.05 |
Formulary
|
NICE TA457 : Carfilzomib for previously treated multiple myeloma |
Carfilzomib |
08.01.05 |
Formulary
|
NICE TA657: Carfilzomib for previously treated multiple myeloma |
Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
Cenegermin |
11.04 |
Non Formulary
|
NICE TA532: Cenegermin for treating neurotrophic keratitis |
Ceritinib |
08.01.05 |
Formulary
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
Certolizumab 200mg |
13.05.03 |
Formulary
|
NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis April 2019 |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA145: Head and neck cancer - cetuximab |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
Ciclosporin |
11.99.99.99 |
Non Formulary
|
NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
Ciclosporin |
11.08.01 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
Ciclosporin |
11.08.01 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
Ciclosporin |
16.11 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117 Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy |
Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
Clearfilm |
A5.02.02 |
Non Formulary
|
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea |
Clomifene Citrate |
06.05.01 |
Formulary
|
NICE CG156 Sept 2017: Fertility problems: assessment and treatment |
Cobimetinib |
08.02.04 |
Non Formulary
|
NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
Colecalciferol 800 units |
09.06.04 |
Non Formulary
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
Colistimethate |
05.01.07 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
Collagenase |
10.03.01 |
Non Formulary
|
NICE TA459 : Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
Conjugated oestrogens + Bazedoxifene |
06.04.01.01 |
Non Formulary
|
NICE TA443 : Obeticholic acid for treating primary biliary cholangitis |
Crizotinib |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
Crizotinib |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA157: Prevention of VTE after elective hip or knee replacement |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA327: Treatment and secondary prevention of DVT and/or PE |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Prevention of stroke and systemic embolism in people with nonvalvular AF |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA157 Sept 2008: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
Dabrafenib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanom |
Dabrafenib |
08.01.05 |
Formulary
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma |
Dabrafenib |
08.01.05 |
Formulary
|
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
Daclizumab |
08.02.02 |
Non Formulary
|
NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288 November 2016: Dapagliflozin in combination therapy for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418 November 2016 Dapagliflozin in triple therapy for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA597 August 2019: Dapagliflozin with insulin for treating type 1 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 May 2016: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE NG8 June 2015: Chronic kidney disease: managing anaemia |
Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy |
Darolutamide |
08.03.04.02 |
Formulary
|
NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer |
Dasabuvir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
Dasatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Dasatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) |
Defibrotide |
08.01.05 |
Restricted Use
|
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance |
Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
Desmopressin |
06.05.02 |
Formulary
|
NICE CG111 Oct 2010: Bedwetting in under 19s |
Dexamethasone |
11.04.01 |
Formulary
|
NICE TA229: Macular oedema secondary to retinal vein occlusion |
Dexamethasone |
11.04.01 |
Formulary
|
NICE TA460: Non-infectious uveitis |
Dexamethasone |
11.04.01 |
Formulary
|
NICE TA349: Diabetic Macular Oedema |
Dexamfetamine Sulphate |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
Dinutuximab |
08.02.04 |
Formulary
|
NICE TA538: Dinutuximab beta for treating neuroblastoma |
Docetaxel |
08.01.05 |
Formulary
|
NICE TA109: Breast cancer (early) - docetaxel |
Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
Doxorubicin |
08.01.02 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Atrial fibrillation - dronedarone |
Dupilumab |
13.05.03 |
Formulary
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
Durvalumab |
08.01.05 |
Formulary
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation |
Edoxaban |
02.08.02 |
Formulary
|
NICE TA355:Prevention of stroke and systemic embolism in people with nonvalvular AF |
Edoxaban |
02.08.02 |
Formulary
|
NICE TA354: Treatment and secondary prevention of DVT and/or PE |
Elosulfase alfa |
09.08.01 |
Non Formulary
|
NICE Managed Access Agreement Elosulfase alfa for treating mucopolysaccharidosis type IVa |
Elosulfase alfa |
09.08.01 |
Non Formulary
|
NICE HST2 Guidance for treating mucopolysaccaridosis |
Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic ITP |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin for type 2 diabetes |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336 March 2015: Empagliflozin in combination therapy for treating type 2 diabetes |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 May 2016: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Emtricitabine + rilpivirine + tenofovir alafenamide |
05.03.01 |
Non Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
Entecavir |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
Entrecitinib |
08.01.05 |
Formulary
|
NICE TA643 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
Entrecitinib |
08.01.05 |
Formulary
|
NICE TA 644 Entrectinib for treating NTRK fusion-positive solid tumours |
Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for prostate cancer |
Eplerenone |
02.02.03 |
Formulary
|
NICE CG108: Chronic heart failure |
Epoetin alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
Epoetin alfa |
09.01.03 |
Formulary
|
NICE NG8 June 2015: Chronic kidney disease: managing anaemia |
Epoetin beta |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
Epoetin beta |
09.01.03 |
Formulary
|
NICE NG8 June 2015: Chronic kidney disease: managing anaemia |
Eribulin |
08.01.05 |
Formulary
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib |
Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib |
Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572 March 2019: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA 583 June 2019 - Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
Esomeprazole |
01.03.05 |
Formulary
|
NICE Pathway: Helicobacter pylori testing and eradication in adults |
Etanercept |
10.01.03 |
Non Formulary
|
NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Etanercept |
10.01.03 |
Non Formulary
|
NICE TA199: Psoriatic arthritis |
Etanercept |
10.01.03 |
Non Formulary
|
NICE TA35: Adult psoriasis |
Etanercept |
10.01.03 |
Non Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Etanercept |
10.01.03 |
Non Formulary
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
Etanercept |
10.01.03 |
Non Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Etanercept |
10.01.03 |
Non Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA |
Etanercept |
13.05.03 |
Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Etanercept |
10.01.03 |
Formulary
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
Etelcalcetide |
09.05.01.02 |
Non Formulary
|
NICE TA448 June 2017: Etelcalcetide for treating secondary hyperparathyroidism |
Everolimus |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
Everolimus |
08.01.05 |
Formulary
|
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment |
Everolimus |
08.01.05 |
Formulary
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
Everolimus |
08.01.05 |
Formulary
|
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
Febuxostat |
10.01.04 |
Formulary
|
NICE TA164 Dec 2008: Febuxostat for the management of hyperuricaemia in people with gout |
Febuxostat |
10.01.04 |
Non Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
Fentanyl |
04.07.02 |
Formulary
|
BNF opiate conversion information |
Fentanyl |
21.01.01.02 |
Formulary
|
BNF opiate conversion information |
Finasteride |
06.04.02 |
Formulary
|
NICE CG97 Lower urinary tract symptoms: quick reference guide |
Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
Fluocinolone |
11.04.01 |
Formulary
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
Fluocinolone |
11.04.01 |
Formulary
|
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA631 Fremanezumab for preventing migraine |
Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer (not recommended) |
Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (not recommended) |
Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Galcanezumab |
04.07.04.02 |
Formulary
|
NICE TA659 Galcanezumab for preventing migraine |
Gastrocote |
08.01 |
Formulary
|
NICE |
Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
Gemcitabine |
08.01.03 |
Formulary
|
NICE TA25: Pancreatic cancer - gemcitabine |
GEMTUZUMAB - OZOGAMICIN Injection 5 mg |
20 |
Non Formulary
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
Gilteritinib |
08.01.05 |
Formulary
|
NICE TA642 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
Glecaprevir / Pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
Glycopyrronium |
16.16 |
Formulary
|
NICE NG62 Cerebral palsy in under 25s: assessment and management Jan 2017 |
Golimumab |
10.01.03 |
Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
Golimumab |
10.01.03 |
Formulary
|
NICE TA375 January 2016: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Golimumab |
10.01.03 |
Formulary
|
NICE TA383 February 2016: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Golimumab |
10.01.03 |
Formulary
|
NICE TA220 April 2011: Golimumab for the treatment of psoriatic arthritis |
Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Golimumab |
10.01.03 |
Non Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Golimumab |
10.01.03 |
Non Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Golimumab |
10.01.03 |
Non Formulary
|
NICE TA220: psoriatic arthritis |
Guanfacine |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
Guselkumab |
13.05.03 |
Formulary
|
NICE TA521 : Guselkumab for treating moderate to severe plaque psoriasis |
Hydrogen Peroxide |
13.11.06 |
Formulary
|
NICE NG153 Impetigo: Antimicrobial prescribing - Visual summary |
Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
Ibuprofen |
10.03.02 |
Formulary
|
Osteoarthritis: care and management |
Idelalisib |
08.01.05 |
Formulary
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib |
Imatinib |
08.01.05 |
Formulary
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
Imatinib (Generic) |
08.01.05 |
Formulary
|
NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Imatinib (Generic) |
08.01.05 |
Formulary
|
NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Infliximab |
01.05.03 |
Non Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
Infliximab |
01.05.03 |
Non Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
Infliximab |
01.05.03 |
Non Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Infliximab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Infliximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
Infliximab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Infliximab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
Infliximab |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for psoriasis |
Injection Device |
06.01.01.03 |
Formulary
|
NICE TA442 : Ixekizumab for treating moderate to severe plaque psoriasis |
Inotuzumab Ozogamicin |
08.01.05 |
Formulary
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
Interferon Alfa 2a |
08.02.04 |
Formulary
|
NICE TA75: Interferon Alfa - Chronic Hepatitis C |
Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
Ipilimumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
Isatuximab |
08.01.05 |
Formulary
|
NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma |
Ivabradine |
02.06.03 |
Formulary
|
NICE TA267 Nov 2012: Ivabradine for treating chronic heart failure |
Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
Ixekizumab |
10.01.03 |
Formulary
|
NICE TA537 August 2018: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Ixekizumab |
13.05.03 |
Formulary
|
NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis |
Ixekizumab |
13.05.03 |
Formulary
|
NICE TA537 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Ixekizumab |
13.05.02 |
Formulary
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Lamivudine |
05.03.03.01 |
Formulary
|
NICE CG165: Chronic Hepatitis B |
Lansoprazole |
01.03.05 |
Formulary
|
NICE Pathway: Helicobacter pylori testing and eradication in adults |
Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
Ledipasvir and Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
Ledipasvir and Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA430 : Sofosbuvir–velpatasvir for treating chronic hepatitis C |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 586 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA587 Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
Lenvatinib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
Lenvatinib |
08.01.05 |
Formulary
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |
Lenvatinib with Everolimus |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
Lesinurad |
10.01.04 |
Non Formulary
|
NICE TA506: Lesinurad for treating chronic hyperuricaemia in people with gout |
Liraglutide |
06.01.02.03 |
Formulary
|
NICE TA664: Liraglutide for managing overweight and obesity |
Lisdexamfetamine |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
Lorazepam |
04.01.02 |
Formulary
|
NICE NG10 Violence and aggression: short-term management in mental health, health and community settings May 2015 |
Lumacaftor + Ivacaftor |
03.07 |
Non Formulary
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure Jan 2020 |
Lutetium (177Lu) oxodotreotide |
08.03.04.03 |
Formulary
|
NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours |
Mannitol inhalation |
03.07 |
Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation |
Mepolizumab |
03.04.02 |
Non Formulary
|
NICE TA431 : Mepolizumab for treating severe refractory eosinophilic asthma |
Methylphenidate |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
Methylphenidate |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
Methylprednisolone |
06.03.02 |
Formulary
|
NICE CG186: Multiple Sclerosis; management in primary and secondary care. |
Methylprednisolone Sodium Succinate |
06.03.02 |
Formulary
|
NICE CG186: Multiple Sclerosis; management in primary and secondary care. |
Midostaurin |
08.01.05 |
Formulary
|
NICE TA523: Midostaurin for untreated acute myeloid leukaemia |
Mifamurtide |
08.02.04 |
Formulary
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
Naftidrofuryl |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
Naftidrofuryl |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
Naldemedine |
01.06.06 |
Formulary
|
NICE TA651 Naldemedine for treating opioid-induced constipation |
Nalmefene |
04.10.01 |
Formulary
|
NICE TA325 Nov 2014: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
Naloxegol |
01.06.06 |
Formulary
|
NICE TA345: Naloxegol for treating opioid‑induced constipation |
Naloxegol |
21.01.05 |
Formulary
|
NICE TA345: Naloxegol for treating opioid‑induced constipation |
Naltrexone |
04.10.01 |
Formulary
|
NICE CG115 Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence Feb 2011 |
Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
Naltrexone/ bupropion |
04.05.01 |
Non Formulary
|
Nice TA494: Naltrexone–bupropion for managing overweight and obesity |
Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML |
Nintedanib |
03.11 |
Non Formulary
|
NICE TA347: Recurrent non-small-cell lung cancer |
Nintedanib |
03.11 |
Non Formulary
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
Nintedanib |
08.01.05 |
Formulary
|
NICE TA347 For treating locally advanced, metastatic or locally recurrant non-small-cell lung cancer |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
Obeticholic acid |
01.09.01 |
Restricted Use
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis |
Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA513:Obinutuzumab for untreated advanced follicular lymphoma |
Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
Ocriplasmin |
11.08.02 |
Non Formulary
|
NICE TA297: Ocriplasmin for treating vitreomacular traction |
Ofatumumab |
08.02.03 |
Non Formulary
|
NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL |
Olaparib |
08.02.04 |
Formulary
|
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy |
Olaparib |
08.02.04 |
Formulary
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: Omalizumab for treating allergic asthma |
Omalizumab |
13.05.03 |
Formulary
|
NICE TA339 Omalizumab for previously treated chronic spontaneous urticaria |
Ombitasvir/ paritaprevir/ ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
Omeprazole |
01.03.05 |
Formulary
|
NICE Pathway: Helicobacter pylori testing and eradication in adults |
Osimertinib |
08.02.04 |
Formulary
|
NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
Osimertinib |
08.02.04 |
Formulary
|
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
Paclitaxel |
08.01.05 |
Formulary
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Paclitaxel |
08.01.05 |
Formulary
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Non Formulary
|
NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine |
Padeliporfin |
08.03.04.02 |
Non Formulary
|
NICE TA546: Padeliporfin for untreated localised prostate cancer |
Palbociclib |
08.03.04.01 |
Non Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Palbociclib |
08.01.05 |
Formulary
|
NICE TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic brest cancer |
Palbociclib |
08.01.05 |
Formulary
|
NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Panitumumab |
08.01.05 |
Formulary
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
Panobinostat |
08.02.04 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
Patiromer Sorbitex Calcium |
09.02.01.01 |
Formulary
|
NICE TA623 Patiromer for treating hyperkalaemia |
Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Pazopanib in renal cell cancer |
Pegaspargase |
08.02.04 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA96: Hepatitis B - peginterferon alfa |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Hepatitis C - peginterferon alfa |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
Peginterferon Beta-1a |
08.02.04 |
Formulary
|
Link NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for melanoma after ipilimumab |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (not recommended) |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
Penicillamine |
10.01.03 |
Formulary
|
NICE NG100 Rheumatoid arthritis in adults: management July 2018 |
Pentosan polysulfate sodium |
07.04.03 |
Formulary
|
Nov 2019 NICE TA610 - Pentosan polysulfate sodium for treating bladder pain syndrome |
Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
Pimecrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
Pirfenidone |
03.11 |
Non Formulary
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy |
Polatuzumab vedotin |
08.01.05 |
Formulary
|
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
Pomalidomide |
08.02.04 |
Formulary
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
Pomalidomide |
08.02.04 |
Formulary
|
NICE TA388: Pomalidomide for myeloma |
Ponatinib |
08.01.05 |
Formulary
|
NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
Prasugrel |
02.09 |
Formulary
|
NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel |
Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Constipation (women) - prucalopride |
Radium-223 dichloride |
08.03.04.02 |
Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
Ramucirumab |
08.01.05 |
Non Formulary
|
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA274: Ranibizumab for treating diabetic macular oedema |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA283:Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
Recombinant human erythropoietins |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy |
Recombinant human erythropoietins |
09.01.03 |
Formulary
|
NICE NG8 June 2015: Chronic kidney disease: managing anaemia |
Recombinant human erythropoietins |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
Regorafenib |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
Regorafenib |
08.01.05 |
Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
Reslizumab |
03.04.02 |
Non Formulary
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
Ribavirin |
05.03.05 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
Ribavirin |
05.03.05 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
Ribavirin |
05.03.05 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
Ribavirin |
05.03.05 |
Formulary
|
NICE TA300 Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people November 2013 |
Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA593 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Rifaximin |
05.01.07 |
Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy (March 2015) |
Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
Risankizumab |
13.05.03 |
Formulary
|
NICE TA596 Risankizumab for treating moderate to severe plaque psoriasis August 2019 |
Rituximab |
08.02.03 |
Formulary
|
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
Rituximab |
08.02.03 |
Formulary
|
NICE TA174 Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
Rituximab |
08.02.03 |
Formulary
|
NICE TA226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma |
Rituximab |
08.02.03 |
Formulary
|
NICE TA 243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma |
Rituximab |
08.02.03 |
Formulary
|
NICE TA 137 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma |
Rituximab |
08.02.03 |
Formulary
|
NICE TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193) |
Rituximab |
10.01.03 |
Formulary
|
NICE TA195 August 2010: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
Rituximab |
10.01.03 |
Formulary
|
NICE TA308 March 2014: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
Rituximab (rheumatology) |
10.01.03 |
Non Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: Treatment and secondary prevention of DVT and/or PE |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: Treatment and secondary prevention of DVT and/or PE |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Prevention of stroke and systemic embolism in people with nonvalvular AF |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335: Prevention of adverse outcomes after acute management of ACS with raised biomarkers |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170: Prevention of VTE after elective hip or knee replacement |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170 April 2009: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335 March 2015: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
Roflumilast |
03.03.03 |
Formulary
|
NICE TA461 : Roflumilast for treating chronic obstructive pulmonary disease |
Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources) |
Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE Chronic heart failure: management (visual summary) |
Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE Chronic heart failure: diagnosis (visual summary) |
Sarilumab |
10.01.03 |
Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
Secukinumab |
13.05.03 |
Formulary
|
NICE TA350: Plaque Psoriasis |
Secukinumab |
10.01.03 |
Formulary
|
NICE TA445 May 2017: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Secukinumab |
10.01.03 |
Formulary
|
NICE TA407 September 2017: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
Simeprevir |
05.03.03.02 |
Formulary
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
Siponimod |
08.02.04 |
Formulary
|
NICE TA656: Siponimod for treating secondary progressive multiple sclerosis |
Sipuleucel- T |
20 |
Non Formulary
|
NICE TA322: Sipuleucel-T for prostate cancer |
Sodium Zirconium Cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599 Sodium zirconium cyclosilicate for treating hyperkalaemia |
Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
Sofosbuvir/Velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA430 Sofosbuvir–velpatasvir for treating chronic hepatitis C Jan 2017 |
Sofosbuvir/Velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
Sofosbuvir+Velpatasvir +Voxilaprevir |
05.03.03.02 |
Formulary
|
NICE TA507 Feb 2018: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
Somatropin |
16.06 |
Formulary
|
NICE TA188 Human growth hormone (somatropin) for the treatment of growth failure in children May 2010 |
Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) |
Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Somatropin for growth failure in children |
Sorafenib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
Sorafenib |
08.01.05 |
Formulary
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
Sotagliflozin |
06.01.02.03 |
Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
Sunitinib |
08.01.05 |
Formulary
|
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82 (2004): Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
Tadalafil |
07.04.05 |
Formulary
|
NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) |
Talimogene laherparepvec |
08.01.05 |
Non Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
Tegafur with Uracil |
08.01.03 |
Non Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
Telaprevir |
05.03.03.02 |
Formulary
|
NICE TA252: Telaprevir in hepatitis C |
Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) |
Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil July 2009 |
Tenofovir Disproxil |
05.03.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for relapsing remitting MS |
Teriparatide |
06.06.01 |
Formulary
|
NICE TA 161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
Thalidomide |
08.02.04 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
Thiamine |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
Thiamine |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
Ticagrelor |
02.09 |
Formulary
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
Tildrakizumab 100mg |
13.05.03 |
Formulary
|
NICE TA575 Tildrakizumab for treating moderate to severe plaque psoriasis April 19 |
Tivozanib |
08.01.05 |
Formulary
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
Tivozanib |
08.01.05 |
Formulary
|
Tivozanib for treating advanced renal cell carcinoma |
Tobramycin inhaler |
05.01.04 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
Tocilizumab |
10.01.03 |
Formulary
|
NICE TA238 December 2011: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis |
Tocilizumab |
10.01.03 |
Formulary
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
Tofacitinib |
01.01 |
Non Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
Tofacitinib |
01.01 |
Non Formulary
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
Tofacitinib citrate |
10.01.03 |
Formulary
|
NICE TA543 October 2018: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
Tofacitinib citrate |
10.01.03 |
Formulary
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
Tofacitinib citrate |
01.05.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
Tolvaptan |
06.05.02 |
Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
Tolvaptan |
06.05.02 |
Non Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
Topotecan |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
Trabectedin |
08.01.05 |
Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
Trabectedin |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Trametinib |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
Trametinib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxan |
Treosulfan |
08.01.01 |
Non Formulary
|
NICE TA 640 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
Trifluridine-tipiracil |
08.01.05 |
Formulary
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
Trifluridine-tipracil |
08.01.03 |
Non Formulary
|
NICE TA 405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
Upadacitinib |
10.01.03 |
Formulary
|
NICE TA665: Upadacitinib for treating severe rheumatoid arthritis |
Ustekinumab |
10.01.03 |
Formulary
|
NICE TA340 March 2017 update: Ustekinumab for treating active psoriatic arthritis |
Ustekinumab |
01.05.03 |
Formulary
|
NICE TA456 : Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
Vandetanib |
08.01.05 |
Non Formulary
|
NICE TA550: Vandetanib for treating medullary thyroid cancer |
Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: Vemurafenib for treating malignant melanoma |
Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
Venetoclax |
08.01.05 |
Formulary
|
NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia |
Verteporfin |
11.08.02 |
Non Formulary
|
NICE TA68: Photodynamic therapy for age related macular degeneration |
Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
Vismodegib |
08.01.05 |
Non Formulary
|
NICE TA489: Vismodegib for treating basal cell carcinoma |
Vitamin B & C |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
Vitamin B & C |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
Vortioxetine |
04.03.03 |
Formulary
|
NICE TA367 - Vortioxetine for treating major depressive episodes |
Zolpidem |
04.01.01 |
Non Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |